These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 20620437)

  • 21. Current options for the treatment of idiopathic thrombocytopenic purpura.
    Arnold DM; Kelton JG
    Semin Hematol; 2007 Oct; 44(4 Suppl 5):S12-23. PubMed ID: 18096468
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Treatment of immune thrombocytopenic purpura in adults.
    Bussel J
    Semin Hematol; 2006 Jul; 43(3 Suppl 5):S3-10; discussion S18-9. PubMed ID: 16815346
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pathophysiology and management of primary immune thrombocytopenia.
    Kashiwagi H; Tomiyama Y
    Int J Hematol; 2013 Jul; 98(1):24-33. PubMed ID: 23702914
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Induction of immune tolerance to platelet antigen by short-term thrombopoietin treatment in a mouse model of immune thrombocytopenia.
    Nishimoto T; Numajiri M; Nakazaki H; Okazaki Y; Kuwana M
    Int J Hematol; 2014 Oct; 100(4):341-4. PubMed ID: 25212676
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Immune thrombocytopenia: pathophysiologic and clinical update.
    Stasi R
    Semin Thromb Hemost; 2012 Jul; 38(5):454-62. PubMed ID: 22753097
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Novel approaches in management of immune thrombocytopenia.
    Panzer S
    Thromb Res; 2009; 123 Suppl 2():S51-5. PubMed ID: 19217477
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Biologic aspects of thrombopoietins and the development of therapeutic agents.
    Solberg LA
    Curr Hematol Rep; 2005 Nov; 4(6):423-8. PubMed ID: 16232377
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Role of romiplostim in splenectomized and nonsplenectomized patients with immune thrombocytopenia.
    Perdomo J
    Immunotargets Ther; 2016; 5():1-7. PubMed ID: 27529057
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Rituximab treatment for chronic refractory idiopathic thrombocytopenic purpura.
    Zhou Z; Yang R
    Crit Rev Oncol Hematol; 2008 Jan; 65(1):21-31. PubMed ID: 17681784
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Therapeutic approaches to secondary immune thrombocytopenic purpura.
    Bussel JB
    Semin Hematol; 2009 Jan; 46(1 Suppl 2):S44-58. PubMed ID: 19245934
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Antiplatelet antibodies in chronic immune thrombocytopenia and their role in platelet destruction and defective platelet production.
    McMillan R
    Hematol Oncol Clin North Am; 2009 Dec; 23(6):1163-75. PubMed ID: 19932426
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of splenectomy on immune thrombocytopenic purpura in (NZW x BXSB) F1 mice: analyses of platelet kinetics and anti-platelet antibody production.
    Mizutani H; Furubayashi T; Kashiwagi H; Honda S; Take H; Kurata Y; Yonezawa T; Tarui S; Ikehara S
    Thromb Haemost; 1992 May; 67(5):563-6. PubMed ID: 1519215
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Splenectomy in immune thrombocytopenic purpura: recent controversies and long-term outcomes.
    Kahn MJ; McCrae KR
    Curr Hematol Rep; 2004 Sep; 3(5):317-23. PubMed ID: 15341697
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Eltrombopag, a thrombopoietin- receptor agonist in the treatment of adult chronic immune thrombocytopenia: a review of the efficacy and safety profile.
    Cheng G
    Ther Adv Hematol; 2012 Jun; 3(3):155-64. PubMed ID: 23556122
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy and safety of dapsone as a second-line treatment in non-splenectomized adults with immune thrombocytopenic purpura.
    Vancine-Califani SM; De Paula EV; Ozelo MC; Orsi FL; Fabri DR; Annichino-Bizzacchi JM
    Platelets; 2008 Nov; 19(7):489-95. PubMed ID: 18979360
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Advances in diagnosis and treatment of idiopathic thrombocytopenic purpura].
    Zhao YQ
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2009 Oct; 31(5):517-21. PubMed ID: 19968061
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Toxicities of the thrombopoietic growth factors.
    Cuker A
    Semin Hematol; 2010 Jul; 47(3):289-98. PubMed ID: 20620441
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Current therapeutic strategies and perspectives in refractory ITP: What have we learned recently?
    Lv Y; Shi H; Liu H; Zhou L
    Front Immunol; 2022; 13():953716. PubMed ID: 36003388
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Fostamatinib for the treatment of adult persistent and chronic immune thrombocytopenia: Results of two phase 3, randomized, placebo-controlled trials.
    Bussel J; Arnold DM; Grossbard E; Mayer J; Treliński J; Homenda W; Hellmann A; Windyga J; Sivcheva L; Khalafallah AA; Zaja F; Cooper N; Markovtsov V; Zayed H; Duliege AM
    Am J Hematol; 2018 Jul; 93(7):921-930. PubMed ID: 29696684
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Novel thrombopoietic agents.
    Andemariam B; Psaila B; Bussel JB
    Hematology Am Soc Hematol Educ Program; 2007; ():106-13. PubMed ID: 18024617
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.